Prelude Q3 net loss $30.0M; FDA clears two INDs, halts PRMT5 internal development

Prelude Therapeutics Inc

2022-Q3 EPS reported -$1.84

Net loss of $30.0M ($0.63 per share) vs $30.7M ($0.66) in Q3 2021.
Cash, equivalents & marketable securities $224.0M; runway into Q4 2024.
FDA cleared INDs for PRT3789 (SMARCA2 degrader) and PRT3645 (brain-penetrant CDK4/6 inhibitor).
Discontinues internal PRMT5 program (PRT543, PRT811) to focus on higher-potential assets.
PRT2527 CDK9 Phase 1 dose escalation on track for RP2D by year-end; no dose reduction AEs.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Prelude Therapeutics Inc reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-22-024727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.